# SL-325 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sl-325

> The next catalyst for SL-325, sponsored by Shattuck Labs, Inc. (STTK), is its primary completion, February 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | SL-325 |
| Codes | SL-325 |
| Sponsor | Shattuck Labs, Inc. (STTK) https://sec-api.dev/companies/sttk/catalysts |
| Indications | [crohn's disease](https://sec-api.dev/indications/crohn-s-disease), moderate to severe hidradenitis suppurativa, with trial initiation, [Hidradenitis Suppurativa (HS)](https://sec-api.dev/indications/hidradenitis-suppurativa-hs) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Q3 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2025-08-05, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0001680367-25-000044): "Subject to regulatory alignment, dosing of the first participant in the single-ascending dose (SAD) portion of the trial is expected in the third quarter of 2025, and the multiple-ascending dose (MAD) portion of the trial is expected to commence in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/sttk_2q2025earningsrelease.htm
- SEC Form 10-Q (accession 0001680367-25-000046): "We expect to initiate enrollment in our Phase 1 clinical trial of SL-325 in the third quarter of 2025, and we expect to complete enrollment in the full Phase 1 clinical trial in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1680367/000168036725000046/sttk-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001680367-25-000044): "Shattuck's preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. Shattuck expects to commence a Phase 1 clinical trial in healthy volunteers in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/sttk_2q2025earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-173010): "Shattucks preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. Shattuck expects to commence a Phase 1 clinical trial in healthy volunteers in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1680367/000119312525173010/d12427dex991.htm

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2025-08-14, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0001680367-25-000044): ""We expect to begin enrollment in our Phase 1 clinical trial, subject to regulatory alignment, in healthy volunteers later this quarter, and to complete the trial during the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/sttk_2q2025earningsrelease.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: moderate to severe hidradenitis suppurativa, with trial initiation.
- First seen 2026-03-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-070613): "•Announced plans to initiate the RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in patients with moderate to severe hidradenitis suppurativa, with trial initiation expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1680367/000162828026070613/sttk_3q2026earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-031643): "•Subject to positive Phase 1 data and regulatory alignment, Shattuck expects to initiate a Phase 2 clinical trial of SL-325 in patients with Crohn's disease in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1680367/000162828026031643/sttk_q12026earningspr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-014987): "•Subject to positive Phase 1 data and regulatory alignment, Shattuck expects to initiate a Phase 2 clinical trial of SL-325 in patients with Crohn's disease in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1680367/000162828026014987/sttk_ye2025earningsrelease.htm
- SEC Form 10-Q (accession 0001628280-26-031661): "We expect to initiate a randomized, placebo-controlled Phase 2 clinical trial evaluating SL-325 in patients with Crohn's Disease ("CD") in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1680367/000162828026031661/sttk-20260331.htm
- SEC Form 10-K (accession 0001628280-26-014989): "We expect to initiate a randomized, placebo-controlled Phase 2 clinical trial evaluating SL-325 in patients with Crohn's Disease ("CD") in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1680367/000162828026014989/sttk-20251231.htm
- SEC Form 10-K (accession 0001628280-26-014989): "We expect to complete enrollment in the ongoing Phase 1 clinical trial for SL-325 in healthy volunteers in the second quarter of 2026, and initiate our Phase 2 clinical trial in patients with CD in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1680367/000162828026014989/sttk-20251231.htm
- SEC Form 10-Q (accession 0001628280-26-031661): "In 2026, we anticipate initiating Phase 2 clinical trial(s) for SL-325." https://www.sec.gov/Archives/edgar/data/1680367/000162828026031661/sttk-20260331.htm
- SEC Form 10-K (accession 0001628280-26-014989): "In 2026, we anticipate initiating Phase 2 clinical trial(s) for SL-325." https://www.sec.gov/Archives/edgar/data/1680367/000162828026014989/sttk-20251231.htm

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hidradenitis Suppurativa (HS).
- First seen 2026-11-12T15:32:36.529Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07934017 (A Study of SL-325 in Participants With Hidradenitis Suppurativa): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Shattuck Labs, Inc.." https://clinicaltrials.gov/study/NCT07934017

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hidradenitis Suppurativa (HS).
- First seen 2026-11-12T15:32:36.529Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07934017 (A Study of SL-325 in Participants With Hidradenitis Suppurativa): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Shattuck Labs, Inc.." https://clinicaltrials.gov/study/NCT07934017

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07753850 (A Study of SL-325 in Crohn's Disease Patients): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Shattuck Labs, Inc.." https://clinicaltrials.gov/study/NCT07753850

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07753850 (A Study of SL-325 in Crohn's Disease Patients): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Shattuck Labs, Inc.." https://clinicaltrials.gov/study/NCT07753850

## Same indication

- [Obefazimod](https://sec-api.dev/pdufa/obefazimod) (ABVX)
- [ORKA-002](https://sec-api.dev/pdufa/orka-002) (ORKA)
- [Povofortay (povorcitinib)](https://sec-api.dev/pdufa/povorcitinib) (INCY)
- [SPY072](https://sec-api.dev/pdufa/spy072) (SYRE)
- [APPROACH (tibulizumab)](https://sec-api.dev/pdufa/tibulizumab) (ZURA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sl-325.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SL-325 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sl-325

```bibtex
@misc{secapidev_pdufa_sl_325_20261116,
  title        = {SL-325 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sl-325}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sl_325_20261116","title":"SL-325 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sl-325","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
